Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEDIMMUNE RESPIGAM CANDIDATES IDENTIFIED BY PRUDENTIAL IN PULL-THROUGH PROGRAM; AVAILABLE RESPIGAM MEETS ONLY 40% OF DEMAND; FOLLOW-ON PRODUCT IN PHASE III

Executive Summary

Prudential is identifying infants who fit labeling criteria for use of MedImmune's RespiGam and providing the names of their physicians to the company, MedImmune Director-Managed Care Stephen Collins told a Biotechnology Industry Organization meeting Feb. 11 in Washington, D.C.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029729

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel